
Design and Baseline Characteristics of FINE-HEART: An Integrated Pooled Analysis of Finerenone in >19,000 Participants across 3 Phase III Trials of HF, CKD & T2D



Muthiah Vaduganathan, MD MPH

Brigham and Women's Hospital

Harvard Medical School






<u>Disclosures:</u> Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, BMS, Boehringer Ingelheim, Chiesi, Cytokinetics, Impulse Dynamics, Lexicon Pharmaceuticals, Merck, Novartis, Novo Nordisk, Occlutech, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health



Strong Epidemiological Overlap of Cardiovascular, Metabolic, and Kidney Disorders




B W H

US NHANES Survey Cycles 1999-2020 Ostrominski J...Vaduganathan M. JAMA Cardiology 2023 US NHANES Survey Cycles 2011-2020 Aggarwal R...Vaduganathan M. JAMA 2024



Increasing CKM Overlap in Trials of HFmrEF or HFpEF Over Time






Ostrominski JW...Vaduganathan M. JACC 2024



Could the Non-Steroidal MRA, Finerenone, Modify Risk across the CKM Spectrum?

- Finerenone is a non-steroidal MRA that has been studied in RCTs of patients with T2D and CKD and separately in patients with HF (with and without T2D)
- However, none of these trials were individually powered to evaluate treatment effects on cardiovascular mortality








Design of the FINEARTS-HF Trial

FINEARTS-HF was designed to evaluate the efficacy and safety of finerenone in patients with HF and LVEF ≥40%, with or without diabetes, and across a broad range of renal function



Criteria

Exclusion

Key

- Key Inclusion Criteria
- // Symptomatic HF (NYHA class II-V) with LVEF ≥ 40%
 - *∥ LVEF* ≥ 60% capped at 20%
- // Hospitalized, Recently Hospitalized, or Ambulatory
- // Elevated Natriuretic Peptide Levels (300/900 AF)
- // Structural Heart Disease (LA Enlargement or LVH)
- // Diuretics in the 30d prior to randomization

- // Potassium > 5.0 mmol/L; eGFR <25 mL/min/1.73 m²
- // MRA use 30d prior to randomization
- // MI or PCI 30d prior to randomization
- // Cardiogenic shock
- # History of dilated, peripartum, chemotherapy induced, or infiltrative cardiomyopathy (e.g., amyloidosis)
- // Alternative causes of signs or symptoms




validly randomized patients

Vaduganathan M...Solomon SD. EJHF 2024 (in press); Solomon SD...McMurray JJV. EJHF, 2024



Design of the FIDELIO-DKD Trial



- T2D
- CKD
- Optimized RASi for ≥4 weeks
- Serum [K+] ≤4.8 mmol/l


HFrEF with NYHA
Class II–IV

 \mathbf{X}

 Uncontrolled arterial hypertension



Design of the FIGARO-DKD Trial



Time to CV death, non-fatal MI, nonfatal stroke or hospitalisation for HF

Time to kidney failure, sustained ≥40% decrease in eGFR from baseline, or renal death

5. Change in UACR

6. Second kidney composite

Key eligibility criteria

- T₂D
- CKD
- Optimized RASi for ≥4 weeks
- Serum [K+] ≤4.8 mmol/l

HFrEF with NYHA Class II–IV

 \mathbf{X}

Uncontrolled arterial hypertension



Pitt B, et al. N Engl J Med 2021




KDIGO Kidney Risk Distribution in FINEARTS-HF

			UACR (mg/g)						
				A1	A2	A3			
				<30	30-300	>300			
5)	G1	≥90		6.3%	2.4%	0.5%			
3	G2	60-89		28.5% 11.2%		2.8%			
FR 1.7	G3a	45-59	45-59 15.4% 8.2% 2.6 %	2.6%					
eGFR (mL/min/1.73 m²)	G3b	30-44		8.7%	6.5%	3.0%			
רי	G4	15-29		1.6%	1.2%	0.9%			
–	G5	<15		0.0%	0.0%	0.0%			
	KDIGO Pick Catagorias								
	KDIGO Risk Categories								
	Low			Moderate	High	Very High			
	34.9%		29.1%	20.2%	15.8%				
		•		·					





KDIGO Kidney Risk Distribution in FIDELIO-DKD and FIGARO-DKD





1. Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int* 2020;98:S1–S115; 2. Bakris G, *et al.* NEJM 2020; 3. Pitt B, *et al.* N Engl J Med 2021; 4. Agarwal R, *et al. Eur Heart J* 2021



Design of FINE-HEART Umbrella Program







FINE-HEART will have increased precision to robustly assess the efficacy and safety of the non-steroidal MRA finerenone on CV death and other cardio-kidney outcomes, and will be enriched for participants with a high burden of CKM multimorbidity.






Baseline Characteristics of FINE-HEART Integrated Population (n=19,027)

	Age	67±10
<u>í</u>	Women	35%
(T)	BMI (kg/m²)	31±6
	Systolic BP (mmHg)	134±15
V-	eGFR (mL/min/1.73m ²)	59±21
	<25	1%
	25 to <45	29%
	45 to <60	26%
	≥60	44%
	UACR (mg/g)	640±913
	A1: <30	20%
	A2: 30 to <300	31%
	A3: ≥300	49%
	Hemoglobin A1c (%)	7.3±1.4
T	History of HF	37%
く	History of Diabetes	81%
	History of AF/AFL	25%
	Diuretic	63%
	ACEi	38%
$\mathbf{\lambda}$	ARB	56%
	SGLT2i	9%





Cardio-Kidney-Metabolic Overlap in FINE-HEART







Thank you

48 countries, 1024 sites, 13,911* participants

Executive committee

George L. Bakris (Principal Investigator); Gerasimos Filippatos; Rajiv Agarwal; Stefan D. Anker; Luis M. Ruilope; Bertram Pitt

Independent data monitoring committee

Murray Epstein; Aldo Maggioni; Glenn Chertow; Gerald DiBona; Tim Friede; Jose Lopez-Sendon; Jean Rouleau

Clinical event committee

Rajiv Agarwal (Chair); Stefan Anker; Phyllis August; Andrew Coats; Hans Diener; Wolfram Döhner; Barry Greenberg; Stephan von Haehling; James Januzzi; Alan Jardine; Carlos Kase; Sankar Navaneethan; Lauren Phillips; Piotr Ponikowski; Pantelis Sarafidis; Titte Srinivas; Turgut Tatlisumak; John Teerlink

National lead investigators

Augusto Vallejos; Richard MacIsaac; Guntram Schernthaner; Pieter Gillard; Maria Eugenia F. Canziani; Theodora Temelkova-Kurktschiev;
Ellen Burgess; Sheldon Tobe; Fernando González; Zhi-Hong Liu; Andrés Ángelo' Cadena Bonfanti; Carlos Francisco Jaramillo; Martin Prazny; Peter Rossing; Jorma Strand; Michel Marre; Roland Schmieder; Christoph Wanner; Pantelis Sarafidis; Juliana Chan; László Rosivall;
Joseph Eustace; Ehud Grossman; Yoram Yagil; Giuseppe Remuzzi; Daisuke Koya; Takashi Wada; Magdalena Madero Rovalo; Ron Gansevoort; Adriaan Kooy; Trine Finnes; Froilan De Leon; Janusz Gumprecht; Fernando Teixeira e Costa; Alexander Dreval; Anantharaman Vathsala; Aslam Amod; Sin Gon Kim; Byung Wan Lee; Julio Pascual Santos; Bengt-Olov Tengmark; Michel Burnier; Chien-Te Lee; SukitYamwong; Ramazan Sari; Kieran McCafferty; Borys Mankovsky; Sharon Adler; Linda Fried; Robert Toto; Mark Williams; Tran Quang Khan



The FIDELIO-DKD team would also like to thank all participating investigators, the centers, the patients and their families

*Number of patients who provided informed consent

(1) FIDELIO-DKD

Thank you

48 countries, 19,381 patients enrolled, 7437 patients randomised

Executive committee

George L. Bakris; Gerasimos Filippatos; Rajiv Agarwal; Stefan D. Anker; Luis M. Ruilope; Bertram Pitt

Independent data monitoring committee

Murray Epstein; Aldo Maggioni; Glenn Chertow; Gerald DiBona; Tim Friede; Jose Lopez-Sendon; Jean Rouleau

Clinical event committee

Rajiv Agarwal; Stefan Anker; Phyllis August; Andrew Coats; Hans Diener; Wolfram Döhner; Barry Greenberg; Stephan von Haehling; James Januzzi; Alan Jardine; Carlos Kase; Sankar Navaneethan; Lauren Phillips; Piotr Ponikowski; Pantelis Sarafidis; Titte Srinivas; Turgut Tatlisumak; John Teerlink

National lead investigators

Augusto Vallejos; Richard MacIsaac; Guntram Schernthaner; Pieter Gillard; Maria Eugenia F. Canziani; Theodora Temelkova-Kurktschiev; Ellen Burgess and Sheldon Tobe; Fernando González; Zhi-Hong Liu; Andrés Ángelo Cadena Bonfanti and Carlos Francisco Jaramillo; Martin Prazny; Peter Rossing; Jorma Strand; Michel Marre; Roland Schmieder and Christoph Wanner; Pantelis A. Sarafidis; Juliana Chan; László Rosivall; Joseph Eustace; Ehud Grossman and Yoram Yagil; Giuseppe Remuzzi; Daisuke Koya and Takashi Wada; Luis Alejandro Nevarez Ruiz; Ron Gansevoort and Adriaan Kooy; Trine Finnes; Froilan De Leon; Janusz Gumprecht; Fernando Teixeira e Costa; Alexander Dreval; Anantharaman Vathsala; Aslam Amod; Sin Gon Kim and Byung Wan Lee; Julio Pascual Santos; Bengt-Olov Tengmark; Michel Burnier; Chien-Te Lee; Sukit Yamwong; Ramazan Sari; Kieran McCafferty; Borys Mankovsky; Sharon Adler, Linda Fried, Robert Toto, and Mark Williams; Tran Quang Khanh



The FIGARO-DKD team would also like to thank all participating investigators, the centres, the patients and their families

Steering Committee

Scott D. Solomon, MD & John J.V. McMurray, MD, Co-Chairs

Carolyn S.P. Lam, MD, Bertram Pitt, MD, Michele Senni, MD, Sanjiv Shah, MD, Adriaan Voors, MD, Faiez Zannad, MD

Sponsor Leadership Bayer

Prabahkar Viswanathan, Ilse van Gameren, Flaviana Amarante, James Lay-Flurrie, Catherine Salt, Michelle King, Richard Nkulikiyinka, Lothar Roessig, Maria Borentain

Clinical Events Committee

Akshay Desai, MD, Pardeep Jhund, MD (Chairs)

Data Safety Monitoring Committee

Aldo Maggione, MD, Murray Epstein, MD (Chairs)

Independent Statistical Team

Brian Claggett,PhD, Muthiah Vaduganathan,PhD, Pardeep Jhund, PhD



FINEARTS-HF

FINerenone trial to investigate Efficacy and sAfety superioR to placebo in paTientS with Heart Failure

National Lead Investigators

Subodh Verma, MD, Mikhail Kosiborod, MD (lead National Lead Investigators)

Argentina	Felipe Martinez	Japan	N. Sato
Australia	J. Atherton	Latvia	G. Latkovskis
Austria	Dirk von Lewinski	Malaysia	Imran Zainal Abidin
Brazil	Jose Francisco Kerr Saraiva	Mexico	Marco Alcocer-Gamba
Bulgaria	Tzvetana Katova	Netherlands	G. Linssen
Canada	S. Zeiroth	New Zealand	R. Troughton
Canada	J.A. Udell	Poland	Grzegorz Gajos.
Canada	S. Verma as NL coordinator	Portugal	Cândida Fonseca
China	Ma chang-sheng	Romania	Ovidiu Chioncel
Colombia	Clara Inés Saldarriaga	Russia	V. Y. Mareev
Czech Rep	Vojtěch Melenovský	Slovakia	Eva Goncalvesova
Denmark	Morten Schou	South-Korea	Seokmin Kang
Finland	Heikki Ukkonen	Spain	Josep Comin Colet
Germany	Johann Bauersachs	Taiwan	Chern-En Chiang
Greece	G. Filipapatos	Turkey	Mehmet Birhan Yılmaz
Hungary	Bela Merkely	UK	Mark Petrie
Hong Kong	Alex Lee	Ukraine	Leonid Voronkov
India	V. Chopra	US	O. Vardeny
Israel Sorel Goland		US	K. Sharma
Italy	Savina Nodari	US	M. Kosiborod

We thank all the FINEARTS-HF Investigators and participants!